Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype

Journal of Inherited Metabolic Disease

Volumn 36, Issue 5, 2013, Pages 787-794

  Van Den Berg, L E M ^a   Drost, M R ^b   Schaart, G ^b   De Laat, J ^a   Van Doorn, P A ^a   Van Der Ploeg, A T ^a   Reuser, A J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DYNAMOMETRY; FEMALE; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PHENOTYPE; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; SUPINE POSITION;

ADOLESCENT; ADULT; BIOPSY; CROSS-SECTIONAL STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MUSCLE FIBERS, SKELETAL; PHENOTYPE;

EID: 84884351695     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9541-7     Document Type: Article

References (36)

1. Bell RD, MacDougall JD, Billeter R, Howald H (1980) Muscle fiber types and morphometric analysis of skeletal msucle in six-year-old children. Med Sci Sports Exerc 12:28-31
2. Drost MR, Schaart G, van Dijk P, et al. (2008) Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 37:251-255
3. Fukuda T, Roberts A, Ahearn M, Zaal K, Ralston E, Plotz PH, Raben N (2006) Autophagy and lysosomes in Pompe disease. Autophagy 2:318-320
4. Giesker D, Bowers GN Jr (1979) The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders. Conn Med 43:699-704
5. Gojo K, Abe S, Ide Y (2002) Characteristics of myofibres in the masseter muscle of mice during postnatal growth period. Anat Histol Embryol 31:105-112
6. Griffin JL (1984) Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 45:23-36
7. Grimby G, Aniansson A, Zetterberg C, Saltin B (1984) Is there a change in relative muscle fibre composition with age? Clin Physiol 4:189-194
8. Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ (2003) Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 1637:164-170
9. Hirschorn R, Reuser A (2001) Glycogen storage disease type II: acid alpha-glucosidase (Acid Maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle MD (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, pp 3389-3420
10. Kishnani PS, Corzo D, Leslie ND, et al. (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329-335
11. Kishnani PS, Corzo D, Nicolino M, et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109
12. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676
13. Kriketos AD, Baur LA, O'Connor J, Carey D, King S, Caterson ID, Storlien LH (1997) Muscle fibre type composition in infant and adult populations and relationships with obesity. Int J Obes Relat Metab Disord 21:796-801
14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121-1123
15. Lexell J (1995) Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 50 Spec No: 11-16
16. Lexell J, Taylor CC, Sjostrom M (1988) What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J Neurol Sci 84:275-294
17. Muller-Felber W, Horvath R, Gempel K, et al. (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17:698-706
18. Raben N, Danon M, Gilbert AL, et al. (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80:159-169
19. Raben N, Fukuda T, Gilbert AL, et al. (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11:48-56
20. Raben N, Ralston E, Chien YH, et al. (2010) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 101:324-331
21. Scelsi R, Marchetti C, Poggi P (1980) Histochemical and ultrastructural aspects of m. vastus lateralis in sedentary old people (age 65-89 years). Acta Neuropathol 51:99-105
22. Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics 5:569-578
23. Schoser BG, Muller-Hocker J, Horvath R, Gempel K, Pongratz D, Lochmuller H, Muller-Felber W (2007) Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol 33:544-559
24. Shea L, Raben N (2009) Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 47(Suppl 1):S42-S47
25. Straub V (2008) Diagnosis. In: Baethmann M, Straub V, Reuser AJJ (eds) Pompe disease. Bremen, UNI-MED, pp 51-54
26. Strothotte S, Strigl-Pill N, Grunert B, et al. (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91-97
27. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208-1220
28. Turner DC, Eppenberger HM (1973) Developmental changes in creatine kinase and aldolase isoenzymes and their possible function in association with contractile elements. Enzyme 15:224-238
29. van Capelle CI, Winkel LP, Hagemans ML, et al. (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18:447-452
30. van den Berg LE, de Vries JM, Verdijk RM, van der Ploeg AT, Reuser AJ, van Doorn PA (2011) A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers. Neuromuscul Disord 21:232-234
31. van den Hout HM, Hop W, van Diggelen OP, et al. (2003) The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332-340
32. Van den Hout JM, Kamphoven JH, Winkel LP, et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448-e457
33. van der Ploeg AT, Clemens PR, Corzo D, et al. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362:1396-1406
34. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT (2005) The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 252:875-884
35. Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT (2003) Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 27:743-751
36. Wokke JH, Escolar DM, Pestronk A, et al. (2008) Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 38:1236-1245